The electrical activity of cardiac tissue is determined by the highly regulated flow of ions across the cell membrane during the cardiac action potential. Ion channels are pore-forming proteins through which these electric currents flow. In this review, the ion currents that underlie the action potential are first described. Then, the way in which expression of individual ion-channel genes results in such ion currents is discussed. Finally, the concept that arrhythmias may be due to abnormalities of structure, function, or number of ion channels, or the way in which they respond to abnormalities in their environment (such as acute ischemia), is reviewed. Further understanding of the molecular mechanisms underlying normal and abnormal cardiac electrophysiologic behavior should allow the development of safer and more effective antiarrhythmic interventions.
INTRODUCTION
Ion channels are proteins that reside in the cell membrane. In response to external stimuli, such as changes in potential across the cell membrane, ion channels can form a pore, which allows movement of ions into or out of cells. The integrated behavior of thousands of ion channels in a single cell results in an ion current, and the integrated behavior of many ion currents makes up the characteristic cardiac action potential. Thus, ion channels are the fundamental building blocks that determine the electrical activity of cardiac tissue. Arrhythmias represent the end product of abnormal ion-channel structure, number, or function. These abnormalities can be primary, or they may be due to other factor(s) in the cell's environment, such as acute ischemia, changes in circulating neurohormones, or intracellular calcium overload, which modify channel function. Traditional approaches to the control of cardiac arrhythmias have relied on drugs that alter this external milieu (e.g. beta-blockers), or drugs that directly activate or, more commonly, block one or more ion current.
The first ion-channel gene was cloned in 1984. The succeeding decade has seen the development of a new field of knowledge that relates an evolving understanding of the physiology of individual ion currents to the molecular mechanisms that underlie them. The implications of this new knowledge are only now being appreciated. It contributes to our understanding of the molecular basis of abnormal electrophysiology in congenital diseases such as the long QT syndrome, and in a wide range of common acquired diseases, such as cardiac hypertrophy or ischemia. With this new knowledge comes the likelihood of improved diagnosis and the possibility of new antiarrhythmic therapies. In this review, the ion currents recorded in normal and abnormal cardiac cells are first described. Then, the concept that individual pore-forming proteins, channels, underlie ion currents is discussed further. Finally, the cloning of individual genes encoding ion-channel proteins and the way in which this new molecular information can impact basic and clinical electrophysiology is reviewed.
MULTIPLE ION CURRENTS UNDERLIE THE ACTION POTENTIAL
The cardiac action potential is the record of voltage across a cardiac cell membrane as a function of time (1). This transmembrane voltage is in turn determined by the flow of individual ions across the cell membrane to form ion currents. The initial application of voltage-clamp techniques to multicellular cardiac preparations allowed identification of major currents flowing during various portions of the cardiac action potential: A large inward sodium current accounts for the rapid phase zero upstroke, and a balance between inward currents (primarily calcium currents) and outward currents (primarily delayed rectifier potassium currents) accounts for the plateau phase and ultimate repolarization (Figure 1 ). The magnitude of an individual ion current may be dependent on many factors, such as the transmembrane potential (itself determined by the magnitude of many ion currents), intracellular calcium, or the presence of blocking drugs. Since the early 1980s, the patch-clamp technique, applied to single cells and to isolated patches of membrane, has been used to further refine this picture. For example, we now appreciate that multiple subtypes of calcium current, with distinctive sensitivities to blocking drugs, may be present in cardiac cells (2). Similarly, at least three types of delayed rectifier potassium currents, I Ks , I Kr , and I Kur , have been identified in heart cells from various species (3-6). I Ks activates very slowly and is increased by β-adrenergic stimulation; I Kr activates more rapidly and is blocked by a number of available or investigational drugs (quinidine, E4031, dofetilide); and I Kur activates "ultra"-rapidly and is blocked by relatively low concentrations of 4-aminopyridine. A third example is the transient outward current, which is responsible for the rapid phase 1 repolarization seen in some cells and which in many species consists of two separate currents (7, 8): I TO1 is activated by membrane depolarization (i.e. after phase 0), whereas I TO2 is activated by increases in intracellular calcium. Sodium, calcium, and transient outward currents share the property that they inactivate: At a given voltage, the current first increases and then, with maintained voltage, its magnitude decreases. This behavior suggests distinct mechanisms are responsible for the increase and the subsequent decrease (or inactivation) of these currents.
Figure 1
The action potential and currents that underlie it. The current amplitudes are not drawn to scale; the peak sodium current is much larger than any of the other currents shown here. Sodium currents, calcium currents, and transient outward currents display inactivating behavior, that is, during maintained depolarization they "turn off." In contrast, delayed rectifiers (IKs, IKr, and IKur) activate and remain activated as long as the membrane potential is depolarized. [Adapted by permission from the Task Force of the Working Group on Arrhythmias (23).]
Heterogeneity of Cardiac Action Potentials
The identification of multiple subtypes of individual ion currents provides an explanation for the increasingly well-recognized heterogeneity of cardiac action potentials as a function of species, development, or disease. For example, in a number of species, action potentials and ion currents recorded in neonatal cells are quite different from those recorded in adult cells (9, 10), presumably reflecting the presence of different ion currents at these time points. However, virtually no information is available on developmental aspects of human electrophysiology. Regional differences in cardiac action potentials provide another example of physiologic heterogeneity. Action potentials recorded from the sinus node and atrioventricular node lack a robust inward sodium current; as a consequence, upstroke slope and impulse propagation are slower than in other regions of the heart. Atrial action potentials are shorter than those recorded in the ventricle. One explanation may be the presence of a very prominent, large repolarizing current, activated by muscarinic agonists, in the atrium. In the ventricle of many species (e.g. dog, guinea pig, human), there is a gradient of action potential configuration and durations across the ventricle wall (11). In addition, a distinctive group of cells (M cells) resembling those in the conducting system has been identified in the midmyocardium. Conducting system cells and M cells have the important characteristic that they prolong markedly with slow stimulation, and an underlying mechanism, decreased I Ks , has been proposed (12). At slow rates, action potentials in these cells not only may prolong markedly, they also may display discontinuities in repolarization (early afterdepolarizations), which are thought to be involved in the genesis of long QT-related arrhythmias (13). Another form of physiologic heterogeneity that has recently been recognized is cell-cell variability, even within the same chamber. For example, among human atrial cells, 29% are reported to display only I TO , 13% display only a delayed rectifier (some combination of I Kr , I Ks , and I Kur ), whereas the remaining cells exhibit both types (14). Thus, even among neighboring cells different ion currents may be recorded.
Action Potentials in Diseased Tissues
Cardiac action potential configuration and duration may be altered in disease, presumably as a consequence of disease-related changes in individual ion currents. For example, action potentials are consistently prolonged when recorded from cardiac cells isolated from hypertrophied hearts (15). The underlying mechanism is a change in the balance between inward and outward currents during the plateau, e.g. increased calcium current or decreased potassium current(s). Action potentials are also prolonged in ventricular myocytes isolated from patients with congestive cardiomyopathy (16). The underlying mechanism in this case appears to be a decrease in transient outward current.
Similarly, action potentials isolated from the border zone of a myocardial infarction (a region thought to be involved in the genesis of reentrant and possibly other arrhythmias) display depressed I TO and sodium current (17). Changes in individual ion currents have also been noted in animal models of acromegaly, thyroid disease, or diabetes (18-20), and the mechanisms are under intensive study. There are important implications of such disease-related changes in individual ion currents. For example, drugs designed to block individual currents will have less, or no, effect if the target current is absent because of cardiac disease. In addition, it is important to recognize that the magnitude of each ion current may be modulated by factors such as membrane potential or intracellular calcium. Thus, a disease-related change in a single ion current may, in turn, produce profound changes in the function of other ion currents. Since the action potential represents the integrated behavior of many currents, disease-related changes in one current may produce secondary changes important for arrhythmogenesis. An example is I Kr block: Rather than merely prolonging the action potential (as would expected), block of this current frequently results in early afterdepolarizations (an arrhythmogenic event), likely the result, at least in part, of altered calcium current function (13, 21).
Ion Currents as Targets of Antiarrhythmic Drug Action
The first drugs widely used for the management of cardiac arrhythmias, digitalis and quinidine, were introduced into therapy without there being knowledge of underlying cellular or molecular mechanisms of action. With the identification of individual ion currents has come the ability to target specific currents for suppression by new drugs. Further, detailed analysis of the dependence of drug block on factors such as membrane potential or stimulation frequency has led to an ability to subclassify antiarrhythmic drug effects on individual ion currents (22). Although classification schemes have some merit in that drugs of a similar class may exert generally similar antiarrhythmic and proarrhythmic effects, overlap among members of the same class is far from complete (23). An evolving understanding of the molecular basis of the interaction between drugs and ion channels should allow greater understanding of these subtle, but potentially clinically important, differences.
A major liability of currently available antiarrhythmic drug therapy is the potential that drugs may provoke new arrhythmias rather than suppress them (24). The mechanisms underlying many of these proarrhythmic syndromes have been relatively well worked out. For example, in the Cardiac Arrhythmia Suppression Trial (CAST), mortality among patients convalescing from a myocardial infarction and treated with the potent sodium-channel blockers encainide or flecainide was double that of patients treated with placebo (25). A likely mechanism appears to be marked conduction slowing, with resultant increases in reentrant excitation, in the presence of the drugs and transient myocardial ischemia. The results of CAST prompted drug development efforts to move to action potential prolongation as an antiarrhythmic mode of action. This class-III strategy is well supported by animal studies (26). However, many new class-III drugs have the liability that they can, in occasional patients, produce marked action potential prolongation with resultant polymorphic ventricular tachycardia, the acquired long QT/Torsades de Pointes syndrome (13). It now appears likely that many of the newly developed class-III antiarrhythmics that share this property also target I Kr (27). Whether or not this is the most appropriate molecular target to achieve the class-III goal of action potential prolongation remains to be determined (see below); the identification of other ion currents controlling repolarization raises the possibility that drugs that target other channels might be effective class-III antiarrhythmics, without the risk of Torsades de Pointes. Although this approach seems attractive, it remains to be established that block of any ion channel can provide truly safe and effective antiarrhythmic therapy. The only currently available drugs shown to reduce mortality due to arrhythmias are beta-blockers (28) and, possibly, amiodarone (29); the former have no direct channelblocking effect and the latter blocks many channels and also exerts antiadrenergic actions.
INDIVIDUAL ION CHANNELS PRODUCE ION CURRENTS
The pioneering work of Hodgkin & Huxley postulated the existence of elementary channels that, under an external influence such as a change in membrane potential, would form a pore to allow ions to move across the cell membrane (30). Over the subsequent three decades, advances in electrophysiology allowed inferences on the putative structure of ion channels. It was postulated that the channel structure was likely a glycosylated protein, with individual amino acid domains subserving important channel functions, such as sensing voltage, acting as a selectivity filter in a permeation pathway across the membrane to allow entry or egress of only selected ions, or binding drugs or toxins (1). Thus, although the molecular structure of individual ion channels remained unknown, the major features of that molecular structure had already been inferred prior to the cloning of ion channels. Indeed, with the application of the patch-clamp technique, it became possible in the early 1980s to describe not simply the behavior of ion currents (the sum of the behaviors of many individual ion channels), but, in fact, to observe the behavior of those single channels (31). Since the isolation of a complementary DNA (cDNA) encoding the electric eel sodium channel (32), literally dozens of ion-channel genes have been described in a wide range of species. The cardiac sodium channel, L-type calcium channel, and many potassium channels (of the Shaker, or Kv1.x, superfamily) share a common structural motif, presented in Figure 2 . For the potassium channels, the deduced amino acid sequence includes six membranespanning segments; four individual channel proteins are thought to coassemble to form functional channels (33). The sodium-and calcium-channel gene Figure 2 Structure of the human cardiac sodium channel. The human cardiac sodium-channel gene SCN5A encodes a protein 2016 amino acids long. The protein consists of four homologous domains, labeled I-IV. Each domain contains six putative transmembrane segments, designated S1-S6. The protein folds upon itself to form a pore whose walls are lined by the S5-S6 loop of each of the four domains, as indicated in the lower left. Regions that subserve important channel functions have been identified by the site-directed mutagenesis approach described in the text, and several are indicated here. For example, the S4 segment is thought to act as a voltage sensor because, in each of the four domains, it is arranged in alpha helical fashion, with each third residue being positively charged. This arrangement of the S4 segment of the 4th domain, spanning amino acids 1623-1645, is shown in the lower right (each letter corresponds to a single amino acid). Another important region is the linker at positions 1471-1523, joining domains III and IV. This small stretch of amino acids is critical for normal sodium-channel inactivation; deletion of amino acids 1505-1507 [K(lysine)-P(proline)-Q(glutamine)] produces the long QT syndrome. Two other recently identified mutations that can also produce the syndrome are indicated. Sodium channel-blocking drugs probably bind to at least residues in the S6 segment of domain IV. Tetrodotoxin, a specific sodium-channel toxin, binds with high affinity to channels in brain and skeletal muscle, and with low affinity to those in heart muscle; a key residue controlling this difference is the cysteine at position 373 in the heart channel (which is an aromatic residue in the other channels). A β1 subunit associated with the sodium-channel protein has been identified in heart and other tissues, but its role in modifying the function of the cardiac sodium channel is not established. Calcium channels have a very similar topology to that indicated here and are, in the heart, associated with ancillary subunits. Potassium channel proteins of the Shaker superfamily have a topology very similar to a single one of the four domains; it is thought that four Shaker proteins coassemble to form functional channels. products are roughly four times the size of the potassium channels and contain four homologous domains each with the six membrane-spanning segment motif. A single sodium-or calcium-channel gene product is sufficient to result in a functional channel. Genes encoding proteins that seem to act as channels but have little, or even no, homology to this common structural motif have also been cloned (34).
THE IMPACT OF ION-CHANNEL GENE CLONING
The availability of genes that encode ion-channel proteins has allowed scientists in this area to ask questions that heretofore have been unaddressable. One powerful tool has been injection of messenger RNA (mRNA) derived from ion-channel genes into heterologous expression systems, commonly the oocytes of the frog Xenopus laevis, which then results in synthesis and transport of channel protein to the cell membrane. Electrophysiologic testing in such systems then reveals the functional features of the ion channels encoded by the mRNA. The mRNA can then be mutated and the experiment can be repeated. A natural question raised by the cloning of multiple ion-channel genes is the correspondence between currents observed in native myocytes and currents encoded by individual cDNAs; in other words, which clones encode which channels? Accumulating evidence strongly suggests that most ion channels are actually complexes of multiple proteins, encoded by different genes. A number of studies now suggest that different Shaker potassium-channel gene products may coassemble to form ion channels with electrophysiologic characteristics typical of neither channel when expressed alone (35, 36). More recently, ancillary subunits have been cloned for sodium, calcium, and potassium channels. These do not themselves encode ion channels when expressed alone but highly modify level of expression or the activation or inactivation characteristics of the target proteins to which they bind. The role of these subunits in modulating channel function in individual cells types is under intensive investigation. For example, expression of the rat brain sodium channel alone results in a slowly activating, slowly inactivating sodium current, whereas coexpression of the channel with its β 1 ancillary subunit results in a current that activates and inactivates much more rapidly, like that observed in native tissue (37). In contrast, the role of the β 1 subunit in mediating expression of cardiac sodium channels seems much less clear, with some studies suggesting the subunit serves little physiologic function (38). In the case of Shaker potassium channels, β-subunits appear to play a role both in inactiva-tion as well as in determining overall current amplitude (39-41). The correspondence among individual ion currents, the ion-channel genes whose expression determines these currents, and the effects of commonly used antiarrhythmic drugs on those currents are presented in Table 1 .
In contemporary molecular terms, the variability in cardiac action potentials discussed above strongly suggests substantial variability (physiologic and pathologic) in expression of individual ion-channel genes whose product proteins constitute individual ion-channel complexes. Thus, an emerging area of study is the factor(s) regulating expression of individual ion-channel genes. Regulation can be at multiple levels, e.g. gene transcription or mRNA editing or stability. Little data are yet available on the molecular determinants of normal and abnormal ion-channel expression; some studies do point to a role for thyroid hormone, for intracellular cyclic adenosine 3 ′ ,5 ′ -monophosphate (cAMP), intracellular calcium, or membrane depolarization (42-44). Inward and outward Na-Ca exchanger Na-Ca exchanger (66) a Subunits that may be important for channel function have been identified. CFTR, Cystic fibrosis transport regulator; IRK, inward rectifier-potassium; GIRK, G-protein-modulated IRK; HERG, human eag-related gene; CIR, cardiac inward rectifier; -, no clone yet reported b ++, clinically important channel-blocking action; sotalol and amiodarone also exert prominent anti-adrenergic actions.
c +, Channel-blocking action demonstrated; clinical importance uncertain.
Ion Channels in Disease
One of the most exciting recent advances in the molecular physiology of ion channels has been the identification of mutations in specific ion-channel genes in some patients with the congenital long QT syndromes. It is now apparent that lesions on at least four chromosomal loci can produce the long QT phenotype (45) . Mutations in ion-channel genes have been associated with two of these chromosomal locations. A mutation in the gene on chromosome 3 encoding the cardiac sodium channel (termed SCN5A) appears to cause the long QT syndrome in some patients (46) , and a mutation in the gene on chromosome 7 encoding the human eag-related gene (HERG) (whose expression seems to result in I Kr ) is responsible in others (47, 48) . Loci have been identified on chromosomes 4 and 11, but specific mutations in genes encoding ion channels, or other proteins, have not yet been identified. In addition, other families have been identified not linked to any of these four loci.
A candidate gene approach identified mutations in the sodium channel in some affected families. First, families with the defect linked to a site on chromosome 3 were found (45) , and at the same time the cardiac sodium-channel gene was localized near this site (49) . These findings allowed geneticists to focus on this gene in these families, and mutations in the gene in affected individuals were identified (46) . One mutation is a 9-nucleotide deletion in the linker between domains III and IV (Figure 2 ), a region of the protein important for normal inactivation (50) . When expressed in Xenopus oocytes, the mutant channel activates and inactivates near-normally. However, with long pulses, the mutant channel passes a small inward current whereas the wild type does not (51) . This aberrant behavior is due to a failure (about 3% of the time) of the channel protein to remain closed during the plateau. This subtle change seems sufficient to upset the normal balance between inward and outward currents during the plateau to prolong the action potential. This is also consistent with autosomal dominant inheritance, since only some sodium channels need be abnormal to explain the defect. Recently, two other mutations in SCN5A have been identified in other families (51a). Both are point mutations (see Figure 2) ; the functional characteristics of these mutant channels have not yet been reported.
The studies of families with congenital long QT syndrome linked to chromosome 7 used a similar candidate gene approach. Interestingly, until these studies were accomplished, a cDNA encoding I Kr , a common target for antiarrhythmic drug block, had not been isolated. HERG was first isolated to chromosome 7 (52), and then families with the long QT syndrome linked to chromosome 7 were identified (45) . Mutations in the gene were found in affected individuals (47) , strongly suggesting that the channel would be defective in the long QT syndrome. Since the topology of the encoded protein seemed to resemble a Shaker-like channel, it was assumed that the lesion would be a decrease in a potassium current, with resultant action potential prolongation. It was only then that wild-type HERG was expressed in Xenopus oocytes and shown to strongly resemble I Kr (48) . Some of the reported mutations are single amino acid substitutions and may result in an abnormal, but functional, protein. Others seem to be much more severe and are likely to result in nonfunctional proteins. Since the HERG gene product, like members of the Shaker superfamily, probably assembles as a multimeric ion channel, the presence of even a single abnormal gene product might be sufficient to completely disrupt channel function. This dominant-negative effect could then account for decreased I Kr in families linked to chromosome 7 and would also be consistent with the autosomal dominant pattern of inheritance.
The tight linkage of a lesion in a gene important for expression of I Kr and the congenital long QT syndrome then naturally raises the question of whether I Kr is an appropriate target for antiarrhythmic drug block. Certainly, the characteristic toxicity of I Kr blockers is long QT-associated polymorphic ventricular tachycardia (Torsades de Pointes) very similar to that seen in the congenital long QT syndrome. It might be argued that in the diseased heart, I Kr block might be beneficial (perhaps with a smaller risk of long QT-associated arrhythmias), but this notion remains to be proven; a large multicenter trial is currently under way that will test this for at least one drug, dofetilide. Because action potential prolongation produces a range of desirable electrophysiologic effects (26), the identification of lesions in I Kr in the congenital long QT syndromes suggests that drugs that block other channels to accomplish action potential prolongation might be safer. The cloning of genes that encode individual ion-channel proteins may allow such a directed drug development strategy to go forward.
Recognition that abnormal electrophysiology can result in defined abnormalities in ion-channel gene structure or gene regulation then raises the natural question of whether or not therapy specifically targeted at defined lesions can be undertaken. For example, blockers of abnormally functioning sodium channels in chromosome 3 patients might be highly effective but would not be as useful in other forms of the congenital long QT syndrome. In patients with an I Kr lesion, some intervention that promoted coassembly of normal HERG gene products (derived from an unaffected parent) and excluded expression of abnormal HERG gene products would be more desirable. It has been suggested that the high incidence of sudden death in the dilated cardiomyopathies may be related in part to action potential prolongation due to defective I TO (53) . In this case, therapy aimed at promoting expression of I TO might result in action potential shortening. Such therapy could be a drug whose action is to promote expression of new I TO channels, or a gene that encodes a repolarizing current.
A danger with this strategy is excessive action potential shortening, which could be highly arrhythmogenic, especially if it were heterogenous. Cellular electrophysiology is now moving away from the description of action potential abnormalities to a more molecular approach to the understanding of these abnormalities. It is the great hope that the identification of such molecular lesions will make way for the development of new gene or drug therapies to correct them. The way in which the behavior of many ion-channel gene products results in the action potential reinforces the concept that interfering at the level of the single gene may have unpredicted consequences due to secondary perturbations in the behavior of other, functionally normal channels. Thus, a major challenge for contemporary electrophysiology is to continue to develop new molecular information and, at the same time, to integrate it toward a better understanding of the mechanisms underlying normal and abnormal electrophysiology at the cellular and whole heart levels. 
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